Skip to content

Clinical Efficacy and Safety of Xuanfei Tiaochang Decoction in the Treatment of Sepsis-Induced Acute Respiratory Distress Syndrome

Clinical Efficacy and Safety of Xuanfei Tiaochang Decoction in the Treatment of Sepsis-Induced Acute Respiratory Distress Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000007
Enrollment
Unknown
Registered
2026-01-04
Start date
2024-10-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-Associated Acute Respiratory Distress Syndrome

Interventions

The control group.:Conventional medical treatment will be administered, including but not limited to providing respiratory support based on the patients respiratory function, implementing protective l
The intervention group.:Based on the treatment in the control group, the Xuanfei Tiaojiao Decoction will be administered. The decoction will be prepared by the hospital's pharmacy, divided into two ba

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1)Definitive diagnosis of sepsis-induced ARDS; 2)Disease severity classified as mild to moderate (P/F ratio > 100); 3)Meeting the Traditional Chinese Medicine syndrome differentiation criteria for phlegm-heat accumulation in the bowels; 4)Age between 18 and 85 years; 5)Obtained informed consent signed by the patient or their authorized representative.

Exclusion criteria

Exclusion criteria: 1)Patients with uncontrolled gastrointestinal bleeding, intestinal obstruction, gastrointestinal intolerance requiring fasting, or inability to receive enteral nutrition; 2)Participation in other clinical trials within the past three months or currently enrolled in other trials; 3)Suspected or confirmed allergy to the study medication; 4)Refusal of study procedures or refusal of active treatment; 5)Clinically judged to be expected to die within 48 hours; 6)Pregnant or breastfeeding women; 7)Patients with major diseases such as malignant tumors, history of organ transplantation, autoimmune diseases, or severe psychiatric disorders.

Design outcomes

Primary

MeasureTime frame
28-Day Mortality;

Secondary

MeasureTime frame
Complete Blood Count;Tumor Necrosis Factor-a;Arterial Blood Gas Analysis;Procalcitonin;C-Reactive Protein;Interleukin-6;SOFA;APACHE II;Gastrointestinal Dysfunction Score;Abdominal Circumference;Borborygmus;The Rate of Mechanical Ventilation;The Duration of Mechanical Ventilation;Length Of ICU Stay;The Mortality in ICU;TCM syndrome scores;

Countries

China

Contacts

Public ContactHan Yun

Guangdong Provincial Hospital of Traditional Chinese Medicine

hy660960@126.com13802530960

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026